$TLTFF – News – Theralase Technologies Inc. (TLTFF-OTCBB) (TLT.V) is Advancing on its Sales and Marketing Mandate
bullquake Newsletter
News – Theralase Technologies Inc. (TLTFF:OTCBB) ( [LINK: http://finance.yahoo.com/qs=tlt.v] TLT.V) is Advancing on its Sales ——————– [LINK: http://www.facebook.com/people/BullQuake-Stocks/100000308486725] [IMG: facebook] [LINK: https://twitter.com/BullQuake] [IMG: twitter] www.BullQuake.com Recent Winners:CYTR 208%, ATHX Over 55%, DRRX 15% Stocks on Watch: NAVB, CREE, ETRM, ELED, IENT, HCTI****
*TLTFF*- TORONTO, ONTARIO / ACCESSWIRE / April 15, 2014 / Theralase Technologies Inc. (*TLT*.V) (*TLTFF*:OTCBB) announced today that it is advancing on its sales and marketing mandate through the hiring of Mr. Derek Small as Director of Sales and Marketing.
Mr. Small has over 15 years of experience in the sale and marketing of medical devices in Canada and the US. Mr. Small`s background includes growth from $0 to $20 million in annual revenue in 5 years, with increasing roles and responsibilities as a senior sales manager of an US based aesthetic laser company.
Under the leadership of Mr. Small, the vision of the Company for 2014 is to grow its Canadian and US sales and marketing through the hiring of a direct sales force comprised of: Territory Sales Managers, Inside Sales Representatives and marketing personnel. Canada will be subdivided into 3 main territories: Western Canada, Ontario and Eastern Canada, coinciding with the largest Canadian cities of Vancouver, Calgary, Toronto and Montreal, The US will be subdivided into 5 main territories: Northeast, Southeast, Midwest, South and Southwest, coinciding with the largest US cities of New York, Miami, Chicago, Dallas and Los Angeles.
The vision of the Company for 2015 is to grow its international revenue through selection and appointment of master distributors and country- specific distributors, who would retain exclusive distribution rights in a particular territory in exchange for meeting and surpassing minimum quarterly and annual revenue objectives.
Derek Small, Director of Sales and Marketing for Theralase Inc. stated that, “It is a pleasure to join the Theralase team and to execute on their vision. Their current therapeutic laser system, the TLC-1000, is a best-in-class technology that has helped millions of patients eliminate their pain throughout Canada. I look forward to growing the sales and marketing team of Theralase over 2014 and 2015 to achieve the Company`s strategic quarterly and annual revenue objectives. The next generation therapeutic laser and anti-cancer technology that the Company is currently developing will be the catalyst that launches the Company`s revenue into the stratosphere through this newly minted sales and marketing team. The opportunity at Theralase bears close relationship to one of my previous positions, where I dramatically increased the revenue of the organization through the hiring of top-notch sales and marketing talent and the launch of world-class technology. I am confident that I can repeat the same success with Theralase, as their technology is clearly state-of-the-art.” Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated that, “I am delighted that the Company has attracted the talents of an accomplished sales professional, with a strong history of success in significantly increasing medical device company sales from $0 to $20 million in sales in 5 years. Derek has been given the mandate from the Company to assemble a highly skilled team of Territory Sales Managers, Inside Sales Managers and marketing personnel in 2Q2014 and 3Q2014 to execute on the Company`s vision of dramatically growing revenue in 2014 and 2015. I wish Derek success in his current mandate.” “Theralase is preparing to launch its next generation TLC-2000 biofeedback therapeutic laser technology in 4Q2014 that will revolutionize the therapeutic laser industry. This new, patented cold laser technology will provide patient specific treatments that adapt to a patient`s physical characteristics delivering best-in-class performance in the elimination of pain, inflammation and acceleration of tissue healing. The medical community and patients who experience pain have been waiting for a technology of this efficacy and performance to enter the market. Derek will be in charge of launching this new technology in Canada and the US in 4Q2014, through his newly assembled sales and marketing team”, Roger Dumoulin-White, President and CEO of Theralase went on to say.
*
About Theralase Technologies Inc.*
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint conditions. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated.
Additional information is available at www.theralase.com and www.sedar.com .
This press release contains forward-looking statements, which reflect the Company`s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White President & CEO Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225 416.699.LASE (5273) ext. 225 rwhite@theralase.com www.theralase.com *Value Driven Milestones & Upcoming Catalysts*
Q1 12 Successful preclinical studies showing complete destruction of various brain and colon cancer cell lines in-vivo and in live animal trials using Theralase PDCs Q3 12 Bladder Cancer identified as primary target for Advanced Photo Dynamic Therapy in FDA clinical trials Q3 12 Developed commercialization path for PDC technology to FDA Phase 1/2a clinical trials Q4 13 TLC-2000 Therapeutic biofeedback medical laser to be launched to healthcare practitioners Q1 14 Entering FDA phase 1 bladder cancer clinical trials Q4 15 Successfully completed 12 month follow-up of bladder cancer clinical trial.
Also anticipating the upcoming launch of TLC-2000 Biofeedback Therapeutic Laser employing a recurring revenue model. Commence TLC-3000 and PDC small animal in vivo pre-clinical trial for cancer destruction **
=”yui_3_9_1_1_1392993627393_1550″> *About BullQuake.com:*
BullQuake.com is a leader in small cap investor research with over a decade of experience in managing assets, trading, research, and technical analysis.
*Follow BullQuake.com on Twitter*https://twitter.com/bullquake *Follow BullQuake.com on Facebook*https://www.facebook.com/bullquake.stocks Sign up for the free investor news and stock alerts at BullQuake.com http://www.BullQuake.com *Download one of our application:*
*The Stock Quotes & Charts App at*https://play.google.com/store/apps/detailsid=com.StockQuote#t=W251bGwsMSwxLDIxMiwiY29tLlN0b2NrUXVvdGUiXQ..
*The Stock Alerts App at*https://play.google.com/store/apps/detailsid=com.BullQuake&hl=en Disclaimer/ Disclosure: BullQuake.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BullQuake.com has not been compensated for any stocks mentioned in this newsletter for either news publication, dissemination and profile on BullQuake.com and partnering websites. BullQuake.com currently does not hold a position in any stocks mentioned in this newsletter.
——————– DISCLAIMER – This disclaimer is to be read and fully understood before using our site, services, or joining any of our network sitesFacebook, Twitter, Partnering Sites, joining our email list, or subscribing to our text message alerts. BullQuake Marketing LLC, BullQuake.com or its employees are not registered Investment Advisers. Through use of this website viewing or using you agree to hold BullQuake.com its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. BullQuake Marketing LLC is not liable for any investment decisions by its viewers and or subscribers. It is highly recommended that BullQuake.coms viewers and or subscribers speak with a financial adviser, or a broker-dealer before making any investment decisions. BullQuake.com is written and published by BullQuake Marketing LLC, its owner and employees. Readers are advised that all content and information listed on Bullquake.com or provided to you from BullQuake Marketing LLC or its employees is issued solely for informational purposes. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation to buy or sell any securities. BullQuake.com is owned and operated by BullQuake Marketing LLC. BullQuake Marketing LLC engaged in the business of advertising and promoting companies for monetary compensation. Any compensation received by BullQuake Marketing LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BullQuake Marketing LLC has not been compensated for any stocks mentioned in this newsletter. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of said companies of which they plan to liquidate, further understanding that the liquidation of those shares may or may not negatively impact the share price. BullQuake Marketing LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. BullQuake.coms sponsored advertisements do not purport to provide an analysis of any companys financial position, operations or prospects and this is not to be construed as a recommendation by BullQuake.com or an offer or solicitation to buy or sell any security. Neither the owner of BullQuake.com nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Any opinions expressed are subject to change without notice. BullQuake.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, through their website or is available from public sources and BullQuake.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. BullQuake.com does not independently investigate the information. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewers entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit www.BullQuake.com. BullQuake.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.
*BullQuake.com*
P.O. Box 795 200 S WAYNE AVE| Waynesboro, Virginia22980| USA ———————————————————————
Related posts:
- $TLTFF – Destroying Cancer with Light, TLTFF Theralase Technologies Inc
- $TLTFF – Keep a Close Watch on This One
- 4 Undervalued Stocks Set to Make Major Moves on Upcoming Catalyst and a Newly Traded Investment Idea
- News Out! Hybrid’s World Renowned Scientist Publishes Book With Leading Publisher
- Hot_DD,_Recaps_and_Catalysts_–_ETRM,_HCTI,_NVGT,_RGDX